Check for updates

OPEN ACCESS

EDITED AND REVIEWED BY Alessia Vignoli, University of Florence, Italy

*CORRESPONDENCE Laura Moreno, ⊠ Imorenog@med.ucm.es

[†]These authors have contributed equally to this work and share first authorship

⁺These authors have contributed equally to this work and share last authorship

RECEIVED 25 May 2023 ACCEPTED 30 May 2023 PUBLISHED 12 June 2023

CITATION

Morales-Cano D, Izquierdo-García JL, Barreira B, Esquivel-Ruiz S, Callejo M, Pandolfi R, Villa-Valverde P, Rodríguez I, Cogolludo A, Ruiz-Cabello J, Perez-Vizcaino F and Moreno L (2023), Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model. *Front. Pharmacol.* 14:1228923. doi: 10.3389/fphar.2023.1228923

COPYRIGHT

© 2023 Morales-Cano, Izquierdo-García, Barreira, Esquivel-Ruiz, Callejo, Pandolfi, Villa-Valverde, Rodríguez, Cogolludo, Ruiz-Cabello, Perez-Vizcaino and Moreno. This is an open-access article distributed under the terms of the Creative Commons Attribution License

(CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

Daniel Morales-Cano^{1,2,3,4,5†}, Jose Luis Izquierdo-García^{2,6,7†}, Bianca Barreira^{1,2,3}, Sergio Esquivel-Ruiz^{1,2,3}, Maria Callejo^{1,2,3}, Rachele Pandolfi^{1,2,3}, Palmira Villa-Valverde^{2,8}, Ignacio Rodríguez^{2,6}, Angel Cogolludo^{1,2,3}, Jesus Ruiz-Cabello^{2,6,9}, Francisco Perez-Vizcaino^{1,2,3‡} and Laura Moreno^{1,2,3*‡}

¹Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain, ²Ciber Enfermedades Respiratorias (Ciberes), Madrid, Spain, ³Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ⁴Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain, ⁵Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, ⁶Department of Chemistry in Pharmaceutical Sciences, School of Pharmacy, Universidad Complutense de Madrid, Madrid, Spain, ⁷Instituto Pluridisciplinar, Universidad Complutense de Madrid, Madrid, Spain, ⁸ICTS Bioimagen Complutense, Universidad Complutense de Madrid, Madrid, Spain, ⁹Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia San Sebastián, Spain

KEYWORDS

pulmonary hypertension, antiproliferative, metabolomics, combination therapy, right ventricle

A Corrigendum on

Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

by Morales-Cano D, Izquierdo-García JL, Barreira B, Esquivel-Ruiz S, Callejo M, Pandolfi R, Villa-Valverde P, Rodríguez I, Cogolludo A, Ruiz-Cabello J, Perez-Vizcaino F and Moreno L (2023). Front. Pharmacol. 14:1021535. doi: 10.3389/fphar.2023.1021535

In the published article, there was an error in Figure 2 as published. There was a mistake in the identification of two of the panels (B and C) which were described respectively as "(B) systolic PAP (sPAP) and (C) diastolic PAP (dPAP)." The corrected Figure 2, and it is caption, appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.



Treatment with riociguat alone or combined with 5-z-70x0zeaenol attenuates pulmonary hypertension in the Sugen 5426/hypoxia (SuHyp) rat model. (A) Mean pulmonary arterial pressure (mPAP), (B) diastolic PAP (dPAP) and (C) systolic PAP (sPAP) in control (NMX-Vh) and SuHyp rats treated with vehicle, 5Z-7-0x0zeaenol (SuHyp-OXO; 3 mg-kg⁻¹:day⁻¹), riociguat (SuHyp-RIO; 3 mg-kg⁻¹:day⁻¹) or both drugs combined (SuHyp-OXO, 7) mg-kg⁻¹:day⁻¹), riociguat (SuHyp-RIO; 3 mg-kg⁻¹:day⁻¹) or both drugs combined (SuHyp-OXO-RIO). (D) Representative PAP recordings in each treatment group. (E) Right systolic and (F) end-diastolic ventricular pressure (RVSP and RVEDP). (G) Fulton index (ratio between RV and left ventricle plus septum weight) and (H) right ventricular weight relative to total body weight in the different treatment groups. Each bar shows the mean +SEM (n = 6-10 animals in each group). *p < 0.05 versus NMX-Vh and #p < 0.05 versus SuHyp vehicle (One-way ANOVA followed by Bonferroni's post hoc test).

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.